Weingarten Realty Investors to Present at Nareit’s REITworld: 2020 Virtual Investor Conference
Get Alerts WRI Hot Sheet
Join SI Premium – FREE
HOUSTON--(BUSINESS WIRE)-- Weingarten Realty Investors (“Weingarten” or the “Company”) (NYSE: WRI) today announced that Andrew “Drew” Alexander, Chairman, President and Chief Executive Officer, is scheduled to make a presentation at Nareit’s REITworld: 2020 Virtual Investor Conference on Wednesday, November 18, 2020, at 11:30 a.m. ET. To access the Company’s live presentation, attendees are required to register for Nareit’s REITworld, using the complimentary registration link below.
Weingarten Realty Virtual Presentation |
||
Date: |
|
Wednesday, November 18, 2020 |
Time: |
|
11:30 a.m. – 12:00 p.m. ET |
Speaker: |
|
Drew Alexander, Chairman, President and Chief Executive Officer |
Registration: |
|
A link to the webcast will be available for reply for 90 days on the Investor Relations page of the Company’s website at www.weingarten.com.
About Weingarten Realty Investors
Weingarten Realty Investors (NYSE: WRI) is a shopping center owner, manager and developer. At September 30, 2020, the Company owned or operated under long-term leases, either directly or through its interest in real estate joint ventures or partnerships, a total of 162 properties which are located in 15 states spanning the country from coast to coast. These properties represent approximately 31.0 million square feet of which our interests in these properties aggregated approximately 21.0 million square feet of leasable area. To learn more about the Company’s operations and growth strategies, please visit www.weingarten.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005985/en/
Michelle Wiggs, Vice President of Investor Relations, Phone: (713) 866-6050
Source: Weingarten Realty Investors
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Knowles to Participate in Upcoming Baird Conference
- FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
- Xybion Digital Inc. Announces Go-Private Transaction
Create E-mail Alert Related Categories
Business Wire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!